Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma

Anthony MatoLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USACorrespondence[email protected]

Tatyana FeldmanLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA

Tania ZielonkaLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA

Arun SingaviLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA

Gabriella GadalettaLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA

Kathryn WaksmundzkiLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA

Pritish BhattacharyyaLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA

Kar Fai ChowLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA

Xiao YangLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA

David PanushLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA

Harry AgressLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA

Maria RosarioLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA

Christina HowlettLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA;Clinical Assistant Professor, Ernest Mario School of Pharmacy, Rutgers University, Hackensack, NJ, USA

Andrew PecoraLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA

Andre GoyLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA

show all

Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma

Supplementary Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma

Supplementary Material

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date